Literature DB >> 11719283

The putative androgen receptor-A form results from in vitro proteolysis.

C W Gregory1, B He, E M Wilson.   

Abstract

Activation domains in the 114 kDa androgen receptor (AR) NH(2)- and carboxyl-terminal regions are thought to contribute to different extents to AR-mediated transactivation. We investigated using anti-peptide antibodies whether smaller AR forms that migrate like the previously described 87 kDa AR-A occur in vivo resulting in constitutive or increased gene activation. Immunoblots of prostate cancer and fibroblast cell culture extracts revealed 114 and 84 kDa AR forms. Antibody mapping indicated the 84 kDa AR lacked the ligand-binding domain and comigrated with the constitutively active AR fragment AR1-660. AR expressed in COS cells was 114 and 92 kDa. Migration of the 92 kDa AR was slightly slower than that of a 90 kDa expressed fragment that was designed to initiate at the second methionine (residue 189) and lacked the NH(2)-terminal FxxLF interaction sequence. The 92 kDa AR did not result from alternative initiation since it was observed when the second methionine was changed to alanine. Optimization of extraction conditions indicated that both 84 and 92 kDa forms resulted from in vitro proteolytic cleavage and that cleavage by caspase-3 could account for the 92 kDa form. The results suggest that AR forms with gel mobility similar to that of the previously described 87 kDa AR-A result from in vitro proteolytic cleavage of NH(2)- or carboxyl-terminal regions during cell extraction and storage and that smaller forms with increased transcriptional activity do not occur in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719283     DOI: 10.1677/jme.0.0270309

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  22 in total

Review 1.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

2.  Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.

Authors:  Yoshitsugu Mitani; Pulivarthi H Rao; Sankar N Maity; Yu-Chen Lee; Renata Ferrarotto; Julian C Post; Lisa Licitra; Scott M Lippman; Merrill S Kies; Randal S Weber; Carlos Caulin; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

Authors:  James L Mohler; Mark A Titus; Elizabeth M Wilson
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

Review 4.  Androgen receptor and its splice variants in prostate cancer.

Authors:  Simon Haile; Marianne D Sadar
Journal:  Cell Mol Life Sci       Date:  2011-07-12       Impact factor: 9.261

Review 5.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

6.  Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells.

Authors:  Arun Sivanandam; Shalini Murthy; Kannagi Chinnakannu; V Uma Bai; Sahn-Ho Kim; Evelyn R Barrack; Mani Menon; G Prem-Veer Reddy
Journal:  J Cell Physiol       Date:  2011-07       Impact factor: 6.384

7.  ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines.

Authors:  Honglin Chen; Stephen J Libertini; Yu Wang; Hsing-Jien Kung; Paramita Ghosh; Maria Mudryj
Journal:  J Biol Chem       Date:  2009-11-28       Impact factor: 5.157

8.  Androgen receptor is expressed in murine choroid plexus and downregulated by 5alpha-dihydrotestosterone in male and female mice.

Authors:  C Henrique Alves; Isabel Gonçalves; Sílvia Socorro; Graça Baltazar; Telma Quintela; Cecília R A Santos
Journal:  J Mol Neurosci       Date:  2008-11-18       Impact factor: 3.444

9.  The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism.

Authors:  Francesca Tonelli; Manal Alossaimi; Leon Williamson; Rothwelle J Tate; David G Watson; Edmond Chan; Robert Bittman; Nigel J Pyne; Susan Pyne
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 10.  The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.

Authors:  Michael V Fiandalo; Wenjie Wu; James L Mohler
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.